StemCell Therapy

STORY:

When Claire Bertram was starting out as an adult, she did what most people do. She found a career to match her strengths and steer clear of her weaknesses.

Part of that job search was making sure to find a line of work that required the least reliance upon eyesight. Bertram is visually impaired. She was born with no vision in her left eye, and in her right eye she suffers from microphthalmia, a rare condition in which one eyeball is unusually small, creating "very limited version," as Bertram puts it.

During a recent interview at the Oasis Day Spa in Dobbs Ferry, New York, Bertram told Reuters she came up with the idea of becoming a massage therapist from someone else who was brainstorming career choices. But unlike other massage therapists who can employ multiple senses to carry out their work, Bertram must operate without sight.

Bertram downplayed both the challenge and the novelty of working through her disability.

She said she's been aided by a lifetime of "honing" her other senses including feeling and hearing.

The image, however, of a massage therapist working without vision is a striking one, so much so Bertram has had to encounter skeptics during her decade-long career.

"No one's said anything to me personally, like, 'I don't want to work with you.' A lot of people, they're not like that," she recalled. "They're going to tell someone else so they don't have to be put in that awkward situation."

"It's not like we're stupid," she said.

Skeptics among her clients have sought an escape through the front desk.

"Are there customers that come in and may at some time, because of Claire's physical limitations, have trepidation? Yes, that does happen," said spa owner Bruce Schoenberg. "And our answer to them is, 'go in, experience the massage, and if you're not happy at the end of the day, let us know. We'll give you a discount.' But that has never happened."

And the ones who stay, Schoenberg said, are "ashamed in some respects that they had these prejudices against somebody that was sight-impaired and they realize that it was something they shouldn't have been concerned about."

Other massage therapists with vision impairment have written about their ability to thrive on industry websites like "Massage Today" and "Massage Magazine." And the field has long been the province for the visually impaired in several Asian countries.

For Bertram, it's understandable why some might find her success remarkable.

But she shies away from the label.

"Lots of people, things happen to them on a daily basis, some people go blind," she says. "You can cope. You can learn how to live a regular life."

(Production by: Dan Fastenberg and Hussein al Waaile.)

See original here:
'You can cope' - visually impaired massage therapist - Yahoo News UK

Thanksgiving is almost here, so lets talk turkey. Anyone who has ever tried to get a good look at a wild turkey knows they have incredible eyesight.

One moment youre looking at a big bird; then you blink your eyes, and its gone. You swear you didnt move a muscle, but obviously you did. And now, after trees have lost their leaves, the problem is exaggerated.

Whether youre a birder or a hunter, clearer sightlines give a huge advantage to turkeys. A turkeys disappearing act is especially impressive for a bird that can weigh more than 20 pounds, run 25 miles per hour, and fly in short bursts more than 50 miles per hour.

One reason turkeys are so elusive is that their eyes are among the most sophisticated in the vertebrate world. They can detect even slight movements at great distances.

Thats how they detect predators such as coyotes, bobcats and great horned owls.

And if turkeys can avoid approaching predators at a distance, deadly attacks can usually be prevented.

Turkey retinas have seven different types of photoreceptors, one type of rod cell and six different types of cone cells. Rods detect light intensity, and cones detect color.

Human retinas, by comparison, contain just a single type of rod and three types of cones.

Based on the abundance of cone cells, its clear that turkeys have excellent color vision. That makes perfect sense given the brilliant, multicolored, fleshy heads male sport during the spring mating season.

For detecting human threats, however, its one particular type of color-sensitive cone cell that gives turkeys an almost unfair visual advantage.

These cone cells are sensitive to UV light, so they see things that we cannot. (This is also true for many other birds and mammals.)

Turkeys sensitivity to UV light puts inexperienced turkey hunters and birders at a disadvantage. Even if observers remain motionless, clothing can make even a stationary observer impossible to miss.

Laundry detergents that whiten and brighten clothing leave behind a UV residue. And the more often clothing is washed with these detergents, the more UV residue they accumulate.

This is also sometimes true for brand new clothing, even camo gear. Anyone wearing camo clothing or old favorites that have been washed many times almost glow to the eyes of turkeys.

One remedy is to wash your turkey clothing with detergents that do not have brighteners. Read the label.

Turkeys also have excellent peripheral vision. Like most birds their eyes are positioned on the sides of their head giving them a field of view of approximately 270-degrees.

Combine that with a flexible neck that can turn almost completely around, and turkeys can see 360 degrees with just a slight turn of the head. Its no wonder they spook so easily.

Compared to humans binocular, 180-degree field of vision, turkeys dont miss much visually.

One drawback to turkey eyes being positioned on the sides of the head is that they lack three-dimensional vision. Though this would seem to be a significant disadvantage, they compensate by bobbing their head up and down enabling their eyes to gather information about relative distances and apparent depths of field.

So, lacking true 3-D vision is not a problem for turkeys. Thanks to razor-sharp vision, sensitivity to UV light, and near 360-degree field of view, wild turkeys are hyper-vigilant regarding their visual environment.

Thats why getting a good look at them in nature is so difficult. Whether hunting or birding, a better strategy might be to simply watch from a comfortable spot at the base of a big oak tree (they love acorns).

This, however, is probably not a safe tactic during turkey hunting season. As we enjoy Thanksgiving dinner with family and friends this week, appreciate some of the biological adaptations that make turkeys the noble birds that Ben Franklin argued would make a suitable national symbol.

And if its within your means, volunteer or donate some cash to a local church or food bank that provides meals for those less fortunate.

Up-to-date agriculture news in your inbox!

Read this article:
Don't blink: Turkeys have incredible eyesight - Farm and Dairy

In some ways, its appropriate that Im getting my vision fixed in the year 2020.

However, I started 2019 with a column talking about my upcoming operation to fix my cataracts. I wrote about how disconcerting it was seeing my vision get worse and to know that, in another time and place, I would be going blind.

At the time, however, I believed I would be having my cataracts fixed in July. July came without a call from my eye surgeon.

Thanks to some prodding from my eye doctor, I was advised to be patient, and recently I finally got my dates for surgery. My eyes will be fixed with two visits to the surgeon over a two-week period this coming January.

I am overjoyed at getting my eyesight back to normal. Im less overjoyed at the prospect of the operation itself, though Ive been told by those with experience that its nothing to be afraid of.

I am frustrated at the length of time it has taken to go from diagnosis to correction.

This is the situation that critics of Canadas health-care system point to when they deride its shortcomings. Canadas health care is largely based on a triage system. If you are hit by a truck, or suffer a heart attack, and need immediate and serious health care, you get it promptly.

If, on the other hand, your condition is not life-threatening, then you may have to wait, because health care costs money, even if Canadian taxpayers pay less for their system than American taxpayers pay for their far less comprehensive version.

There are limited resources to go around, so the tasks that can wait need to wait for the funding to make them happen. And we end up with waiting lists.

While it makes sense for a health-care system to focus on the person suffering a heart attack ahead of someone who needs arthroscopic surgery on their knee, frustration still builds for the person who has to wait months in knee pain, or lean closer and closer to computer screens he can now hardly read.

More:
Opinion | Glad to be getting eyesight back, frustrated with wait time - Waterloo Chronicle

Nov. 27 To the Editor:

Dear Cousins,

I have never written a holiday letter. I will turn 80 (!) in a few weeks, so we can all agree I'm overdue. And, having experienced a big loss just six months ago, the fact that I have chosen to give thanks for my first ever holiday letter may seem strange.

Forty years ago, as I was approaching my 40th birthday milestone and could anticipate my nest emptying, I reached out to a lifestyle coach named Wynne, who became a mentor and lifelong friend. Every year Wynne would send a note of profound thanks sharing how her life had been enriched that year. She is now into her eighties and is nearly blind due to a progressive degenerative ocular disease. She is still coaching, however. As her eyesight continued to fail, her son said, you may be losing your sight but you will always have vision!

What better time is there to acknowledge vision than as we look to 2020! I have always heard that hindsight is 20/20 but if we revisit the foresightedness combined with courage of those who came before us, that's 20/20 vision! When the four generations of cousins gathered at Jill's wonderful home in July, there were countless thankful moments for me. First, of course, is our mutual gratitude that our ancestors acted upon their vision more than a century ago, when violence was spreading in eastern Europe, and crossed the Atlantic to a life of unknowns. After our lunch, as we listened to the recording of my father's journey to Ellis Island, I looked around the dining table and thanked my grandparents, parents, aunts, uncles and cousins for their collective visions of welcoming everyone into our family no matter his or her race, religion or creed! That was pace setting for their generations and we are all better for it. I am thankful that 20/20 vision is in our genes!

This was a difficult year but I am thankful for having had 57-plus years of marriage and for my two wonderful children who have blessed me with amazing, attentive families. And, there is deep appreciation to all of you who have participated in the collecting and documenting of our history so that future generations will always know how it all began.

I wish you all a wonderful Thanksgiving, Christmas, Hanukkah, whatever you observe or choose not to observe and a healthy, happy 2020.

Lots of love, Linda

Linda Tober

Exeter

See more here:
So much to be thankful for this Thanksgiving - Foster's Daily Democrat

This press release was orginally distributed by SBWire

Hallandale Beach, FL -- (SBWIRE) -- 11/29/2019 -- Most people have eye problems at one time or another. But some people have had a common vision condition, usually present from birth. There could a variety of reasons for early age eye problems and left untreated, they can cause serious damage to an individual's eyes. There are many patients who recognize their eye problems later in life. The 60-year-old south Florida resident, Lydia Harris had spring time cataract surgery to correct High Myopia and cataracts in both eyes by Braverman Eye Center in Hollywood. Before she got to see Dr. Stanley Braverman and his staff in their state-of-the-art office - or be referred by her Optometrist Dr. Dan Llewellyn in Fort Lauderdale, who is the official eye doctor for the Florida Panthers - Harris had endured a lifetime of vision problems.

"Since I was in pre-school, I wore glasses. My eyesight got progressively worse through the years - and even had to wear bifocals that looked like Coke bottles. It was not an easy childhood" Lydia Harris pointed out. "The meeting with Dr. Braverman and his great staff was the beginning of something special. Every question I had, he had an answer for. I can't talk enough about the procedure on both eyes and the way I was treated. A positive experience" she further added.

A month after the procedure was done, she is doing well and enjoying her life like never before. She had an amazing experience at Braverman Eye Center and now recommends people having eye problems to visit this eye center in Hollywood.

Talking about Lydia Harris' eyes problems, Dr. Braverman said "Ms. Harris had two problems. She had cataracts, but she also had highly nearsighted eyes since birth. With today's methods of cataract surgery, we are able to not only correct the cataract, but also, we can change the power of the crystalline lens so that nearsightedness can be eliminated.

About Braverman Eye CenterBraverman Eye Center has built their reputation on integrity and the highest standards of care. They provide high quality eye care to patients throughout South Florida, primarily serving the eye care needs of patients in Hallandale Beach, Hollywood, and many more; however, they do see many patients from other surrounding communities in Dade, Broward and Palm Beach County, Florida. They pride themselves on providing the most efficient, professional and personal Optometric and Ophthalmologic care possible. They will do their best to honor one's trust by providing their patients excellent care and valued respect.

For more information, please visit- https://www.bravermaneyecenter.com

For more information on this press release visit: http://www.sbwire.com/press-releases/a-lifetime-battle-for-lydia-harris-the-60-year-old-south-florida-resident-comes-to-a-happy-end-with-a-visit-to-braverman-eye-center-1266560.htm

See the article here:
A Lifetime Battle for Lydia Harris, the 60-Year-Old South Florida Resident, Comes to a Happy End with a Visit to Braverman Eye Center - Press Release...

Results of a recent study suggest a possible role for tumor necrosis factor- (TNF-) in the development of peripheral neuropathy (PN) in patients with multiple myeloma (MM) treated with bortezomib. The studys results were published in the Annals of Hematology.

Inthis study, patients with MM (N=35) were given a maximum of 8 cycles ofbortezomib in addition to dexamethasone. Patients underwent tests of nervefunction, and their serum levels of TNF- were also measured. This study alsoincluded an analysis of the effects of an anti-TNF- monoclonal antibodytherapy in Wistar rats (N=36) that received bortezomib.

Evaluablepatients were stratified based on the cumulative dosages of bortezomib theyreceived. A total of 16 patients (48.5%) had cumulative dosages of less than 39mg/m2, and 17 (51.5%) each received 39 mg/m2 or more of bortezomib.

Amongpatients who received lower cumulative dosages of bortezomib, 43.8% (n=7)experienced PN, compared with an incidence of PN of 82.4% (n=14) among patientswho received 39 mg/m2 or more of bortezomib (P <.05).Grade 3 PN was reported for 2 patients in the higher-dose group.

Baselineserum TNF- levels did not significantly differ between patients whoexperienced PN and those who did not. With bortezomib treatment, TNF- levelsrose overall, but increases were most significant among patients who developedPN of grades 2 to 3. The investigators also reported that most patients withTNF- levels higher than 65 pg/mL had neuropathy symptoms.

Inthe rat model, poorer nerve conduction velocity and evidence of mechanicalallodynia appeared to be associated with bortezomib therapy. Among rats treatedwith bortezomib, however, treatment with the anti-TNF- monoclonal antibody wasassociated with less neurological dysfunction.

Developmentof new neuroprotective agents against TNF- may be a promising therapeuticstrategy to prevent the development of neuropathy, wrote the studyinvestigators in their report.

Reference

Zhao W, Wang W, Li X, et al. Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-. Ann Hematol. doi: 10.1007/s00277-019-03816-6

Read more from the original source:

Potential Link Between Tumor Necrosis Factor- and Peripheral Neuropathy Observed With Bortezomib Treatment in Multiple Myeloma - Oncology Nurse...

Thediabetic neuropathy markethas witnessed growth from relentless efforts of various healthcare proponents in expanding the array of various therapies and first line drugs in treating the underlying pain. Players have been able to meet the patient needs because of expanding understanding of physiopathology that promote neuropathic pain in diabetes. Most first line drug therapies notably focus on mitigating toxic effects of hyperglycemia. Several players in the diabetic neuropathy market have been benefitting from the introduction of guidelines that help develop therapies that can optimize pain.

The competitive landscape of the diabetic neuropathy market is characterized by fair degree of fragmentation. A handful of players hold sizable shares in the market. Top names in the diabetic neuropathy market are Janssen Pharmaceuticals, Eli Lilly and Company, Cephalon, NeuroMertrix, and Johnson and Johnson. One of the key strategies they increasingly adopt to consolidate their shares is mergers and acquisitions.

During 2017 2025, the global diabetic neuropathy market is expected to clock a CAGR of 5.4%. By the end of this period, the worth of the global market is anticipated to be US$5.718 bn.

Request a PDF Sample of Diabetic Neuropathy MarketReport

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2199

Prevalence and Complexity Of Diabetic Peripheral Neuropathy Represents Unmet Need

Of the various disorder types, diabetic peripheral neuropathy has attracted the attention of pharmaceutical and biotech companies. By 2025-end, the segment is expected to account for a major share in the global diabetic neuropathy market. The complexity of the type has attracted vast attention of the healthcare industries around the world. The marked prevalence of diabetic peripheral neuropathy adds to its disabling nature. The higher mortality and morbidity of distal symmetrical polyneuropathy is also propelling investments in this area in the global diabetic neuropathy market.

In developed nations, the prevalence of diabetes is increasing at rapid pace. According to recently disclosed statistics by International Diabetes Federation, by 2045 629 million people will be living with diabetes, and currently account for more than 12% of the total spending by adult populations. One of the most complication is diabetic neuropathy. Hence, the condition has attracted groundswell of interest in these nations, such as in the U.S. and the U.K. Further, in recent years, a fast emerging category that is attracting attention of companies in the diabetic neuropathy market is treatment-induced neuropathy in diabetes. Constant advances in understanding of the underlying pathogenesis of diabetic peripheral neuropathy over the last decade have expanded the prospects of the diabetic neuropathy market.

Request for a Discount on Diabetic Neuropathy Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2199

Asia Pacific Fast Emerging as Key Diabetic Neuropathy Market

In the light of developed markets, North America and Europe have emerged as prominent regional markets. A shared factor underpinning the evolution of both these markets are expanding interest in pathophysiological mechanisms. On the other hand, Asia Pacific is emerging as a vastly lucrative region in the global diabetic neuropathy market. This is attributed to the substantial clinical developments in understanding diabetic complications.

Expanding Pharmacological Classes of Drugs Provides New Revenue Base

Lifesciences companies in the global diabetic neuropathy market find it worthwhile and necessary to develop therapies that can target multiple metabolic pathways. Key of these are hyperglycemia, toxic adiposity, mitochondrial dysfunction, and polyol pathway. Promising candidates to emerge in recent years are accumulation of advanced glycation end products (AGEs). Growing research on improving the clinical efficacy of antidepressants and anticonvulsants will likely expand the outlook of the global diabetic neuropathy market.

Of note, developed as developed markets are seeing expanding research in pharmacological classes of drugs. The development of these drugs is fueled by the adoption of multimodal and multidisciplinary approaches. Further, growing focus on developing second or third line treatment is also unlocking new potential in the diabetic neuropathy market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving method-ologies and leveraging existing data repositories.TMR believes that unison of solutions for clients-specific problems with right methodology of re-search is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.comBlog:https://theglobalhealthnews.com/

Read this article:

Diabetic Neuropathy Market: Technological Growth Map over Time to Understand the Industry Growth Rate - Montana Ledger

Damage to the nerves that control the regulation of involuntary function due to high levels of blood glucose may cause a condition called autonomic neuropathy. An example of body functions such as heart rate, digestion, blood pressure, sexual activity, and perspiration. Cardiac autonomic neuropathy occurs when the heart is affected by nerve damage. Diabetes mellitus patient commonly suffers from cardiac autonomic neuropathy. More than 26 million people in the Unites States get affected by diabetes mellitus. With the increase in age and duration of diabetes mellitus, a prevalence rate of cardiac autonomic neuropathy increase. Cardiac Autonomic Neuropathy is the reason for several cardiac dysfunctions and many medical symptoms which include exercise intolerance, silent ischemia, postural hypotension, resting tachycardia, perioperative instability, and cardiomyopathy.

To Remain Ahead Of Your Competitors, Request for a Sample Here @https://www.persistencemarketresearch.com/samples/14518

Cardiac Autonomic Neuropathy treatment market involves aggressively treating cardiovascular risk factors like hypertension. Cardiac autonomicdeficiency of essential fatty acids, increased oxidative stress, autoimmune damage, and formation of advanced glycosylation end products. Other therapies include in Cardiac autonomic neuropathy treatment include Aldose reductase inhibitor and angiotensin receptor blocker.

Cardiac Autonomic Neuropathy Treatment Market: Drivers and Restraints

In diabetic patients, Cardiac Autonomic Neuropathy characterizes one of the main causes of morbidity and mortality as well as is responsible for cardiac arrhythmias and sudden death which is increasing the demand for cardiac autonomic neuropathy treatment market. Increase in aging population as the well societal influence and changing lifestyles are also the cause of increasing Cardiac autonomic neuropathy treatment market in the world. According to WHO report, more than 23 million people in the United States and an estimated 250 million worldwide are affected by diabetes mellitus. In diabetic patient Cardiac autonomic neuropathy is very common and leads to abnormalities in heart flow rate as well as vascular and peripheral dynamics and reduced quality of life are the drivers for Cardiac autonomic neuropathy treatment market. Some of the Cardiac autonomic neuropathy therapies has shown promising initial result but yet to be validated as well Cardiac autonomic neuropathy treatment management depends on aggressive strategies due to the absence of direct treatment could be the possible restraint for the Cardiac autonomic neuropathy treatment market. Poor reimbursement policies by government and private players also challenge the Cardiac autonomic neuropathy treatment market.

Cardiac Autonomic Neuropathy Treatment Market: Segmentation

Cardiac autonomic neuropathy treatment market is segmented into treatment type which includes pharmacological agents as well as inhibitors and by distribution channel.

Cardiac Autonomic Neuropathy Treatment Market: Overview

Due to increasing aging population and diabetes mellitus, the global market for Cardiac autonomic neuropathy treatment market is expected to gain pull during the forecast period. It is expected centrally acting Cardiac autonomic neuropathy treatment market segment to hold the dominant share in the global Cardiac autonomic neuropathy treatment market due to increasing number of diabetic patients. Also, the increase in number launches of the new drugs cardiac autonomic neuropathy treatment market is increasing globally. Increasing competition among ading drug firms in the market to develop newer drugs tends to drive the cardiac autonomic neuropathy treatment market towards the growth rate.

Cardiac Autonomic Neuropathy Treatment Market: Region-wise Outlook

Based on geographic region, the Cardiac autonomic neuropathy treatment market is segmented into seven significant regions:

North America, Latin America, Europe, Asia-pacific, and Middle East & Africa.

North America is the largest in Cardiac autonomic neuropathy treatment market, owing to high number of diabetes mellitus patient and awareness among patients regarding the harmful effects orpulation as well as growing healthcare expenditure is the reason for significant revenue generation from this region in Cardiac autonomic neuropathy treatment market. Europe is the second largest in Cardiac autonomic neuropathy market due to advancement in technologies and change in lifestyles.

Asia-Pacific is expected to grow at faster rate in the upcoming period due to the increase in the prevalence of diabetes mellitus thus boosting the Cardiac autonomic neuropathy treatment market growth.

Make An Inquiry To Customize This Report @https://www.persistencemarketresearch.com/request-customization/14518

Cardiac Autonomic Neuropathy Treatment Market: Key Market Participants

Some of the key players in Cardiac autonomic neuropathy treatment market are

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

Read more:

Cardiac Autonomic Neuropathy Treatment Market by Size | Growth | Analysis | Trends and Forecasts to 2017 2025 - chronicles24

Researchers at Griffith University will undertake a comprehensive assessment of nerve function of people with diabetes to learn more about the onset of peripheral neuropathy.

Neuropathy is the highest reported complication of diabetes worldwide. The most common form of neuropathy is distal symmetrical neuropathy. It causes significant suffering, including loss of sensation in the feet and eventually in the hands.

Around 1.7 million Australians have diabetes, according to Diabetes Australia, and around half of those people could be expected to develop some type of neuropathy. The number of people with diabetes has experienced a fourfold increase, from 108 million adults worldwide in 1980 to 422 million in 2014.

Although diabetic neuropathies are common, surprisingly little is known about the condition and its onset, which is why Eva Sierra Silvestre is leading the DIANE (Diabetic neuropathies) research project, which will assess the function, structure and mechanics of the nervous system in people with diabetes.

What we are planning to do is to create a very comprehensive assessment of nerve function in people with diabetes, she said. By doing that, we may be able to predict or be able to improve prevention and management later on.

An issue with this condition and current screening practices is that sometimes the onset can go unnoticed, so the study will aim to find ways to pick up on peripheral neuropathy in its early stages.

Early detection of diabetic complications is crucial for an effective management of the condition, Ms Sierra Silvestre, a PhD candidate at the Menzies Health Institute Queensland, said.

In research, nerve function in the feet has been studied more than in hands. Typically, it is thought that hands are affected in a later stage but the research team thinks that these changes may occur earlier than what we think. As such, the DIANE research project will focus on assessing subjects hands for any sign of nerve damage.

The researchers are looking for people with diabetes, with and without symptoms of peripheral neuropathy, such as numbness or pain.

Participants will be required to attend three sessions, one each at Griffith Universitys Nathan campus, QUT at Kelvin Grove, and QScan at Red Hill.

To learn more about the study, visit the DIANE Diabetic Neuropathies research project website.

Ms Sierra Silvestres study is one of two ongoing into peripheral neuropathies at Griffith University. Dr Brooke Coombes is also looking for study participants as she investigates a new approach to managing exercise for people with the condition.

Read more:

Study to search for early signs of peripheral neuropathy in people with diabetes - Griffith News

Akcea Therapeutics and Ionis Pharmaceuticals announced the launch of a Phase 3 clinical trial evaluating the safety and efficacy of AKCEA-TTR-LRx (ION-682884) for the treatment of adults with familial amyloid polyneuropathy (FAP).

The global, open-label, randomized NEURO-TTRansform trial (NCT04136184) is expected to start in December. It is recruiting approximately 140 participants ages 18 to 82, diagnosed with stage 1 or 2 FAP, at the Ionis Investigative Site in Boston.

AKCEA-TTR-LRx is a second-generation RNA-targeted therapy in development for the treatment of all forms of transthyretin amyloidosis, including the hereditary (hATTR) and wild-type form of the disease (ATTRwt).

It works by preventing the RNA sequence of the TTR gene, which is defective in people with hATTR, from being translated into a protein. This reduces the buildup of abnormal amyloid deposits that accumulate in several tissues, slowly causing damage and eventually giving rise to symptoms associated with FAP or the other form of hATTR, called familial amyloid cardiomyopathy (FAC). Of note, RNA is the molecule that serves as the template for the production of a protein.

AKCEA-TTR-LRx was originally discovered by Ionis through its proprietary LIgand Conjugated Antisense (LICA) technology platform. It is now being co-developed by Ionis and its affiliate, Akcea.

NEURO-TTRansform will compare the effects of AKCEA-TTR-LRxto the placebo arm of a previous Phase 2/3 trial (NCT01737398), also sponsored by Ionis, that investigated the safety and efficacy of Tegsedi(inotersen) in people with FAP, compared with a placebo.

Once enrolled in NEURO-TTRansform, participants will be randomly assigned to receive subcutaneous (under-the-skin) injections of AKCEA-TTR-LRx every four weeks, or Tegsedi once a week. All study participants also will receive daily supplemental doses of the recommended daily allowance of vitamin A.

Those who are initially assigned to Tegsedi (20 out of the 140 expected to enroll), will cross over to AKCEA-TTR-LRx after 35 weeks.

The studys main goals, which will be assessed at 66 weeks, include analyzing changes from the studys start in the levels of TTR found in the serum, as well as changes in the scores of the modified Neuropathy Impairment Score +7 (mNIS+7) and of the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN).

The mNIS+7 is a measure of neurological impairment that evaluates muscle weakness, sensation, reflexes, nerve conduction, and autonomic function; the Norfolk QoL-DN evaluates the impact of neuropathy on individuals quality of life.

An interim analysis is planned at 35 weeks to assess changes from the studys start in the levels of TTR found in the serum and in mNIS+7 scores.

Patients enrolled in NEURO-TTRansform will be followed for 85 weeks. After completing the study, they will have the option to enroll in an open-label extension study.

The initiation of the TTRransform Phase 3 program represents an expansion of our dedication and commitment to the ATTR community. The NEURO-TTRansform study is the first of two Phase 3 studies that we expect to initiate with AKCEA-TTR-LRx. Our Phase 1 data are encouraging and we are excited about the possibility of delivering a significant advancement for people living with hATTR amyloidosis, Damien McDevitt, PhD, Akceas interim CEO, said in a press release.

In a previous Phase 1 trial (NCT03728634) sponsored by Ionis, it was shown that monthly 90-mg injections of AKCEA-TTR-LRx could lower the levels of transthyretin (TTR), the protein involved in FAP, by up to 94% after 13 weeks of treatment in a group of healthy volunteers.

The Phase 1 data of AKCEA-TTR-LRx are consistent with the clinical profile seen across our other LICA programs, highlighting the potential of LICA-engineered therapies to address both rare and more common diseases, said Brett P. Monia, PhD, chief operating officer of Ionis.

We remain dedicated to advancing this important clinical development program as rapidly as possible and are hopeful about the prospect of bringing a new safe and effective treatment to people living with the devastating symptoms of hATTR amyloidosis in the years ahead, Monia added.

The company also launched the Phase 3 CARDIO-TTRansform clinical trial (NCT04136171), to test AKCEA-TTR-LRx in people with transthyretinmediated amyloid cardiomyopathy (ATTR CM), or FAC. The trial is not yet enrolling.

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that make up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 2

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Read this article:

Phase 3 Trial of Investigative FAP Therapy AKCEA-TTR-LRx Launching - FAP News Today

Nov 29, 2019 (Thomson StreetEvents) -- Edited Transcript of Marker Therapeutics Inc earnings conference call or presentation Tuesday, November 12, 2019 at 10:00:00pm GMT

* Anthony H. Kim

Marker Therapeutics, Inc. - CFO

Marker Therapeutics, Inc. - SVP of Clinical Development

* Peter L. Hoang

Marker Therapeutics, Inc. - President, CEO & Director

Roth Capital Partners, LLC, Research Division - MD, Senior Equity Analyst & Head of Biotechnology Research

Nomura Securities Co. Ltd., Research Division - Research Analyst

Oppenheimer & Co. Inc., Research Division - Associate

Janney Montgomery Scott LLC, Research Division - Equity Research Analyst & Director of Biotechnology Research

Greetings, and welcome to the Marker Therapeutics Third Quarter 2019 Operating and Financial Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to our host, Tony Kim, Chief Financial Officer. Thank you. You may begin.

Anthony H. Kim, Marker Therapeutics, Inc. - CFO [2]

Thank you, and welcome, everyone, to our third quarter 2019 earnings call. The press release reporting our financial results is available in the News section of our corporate website at markertherapeutics.com. Joining me for the call today are Peter Hoang, our President and Chief Executive Officer; Dr. Juan Vera, Chief Development Officer; and Dr. Mythili Koneru, Senior Vice President of Clinical Development.

As a reminder, we will be making forward-looking statements during today's call. These statements are subject to risks and uncertainties that may cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent Form 10-Q on file with the SEC.

I would now like to turn the call over to Peter Hoang.

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [3]

Thank you, Tony. Good afternoon, everyone, and thanks for joining us.

We continue to make progress advancing our MultiTAA T cell therapies across various hematologic and solid tumor cancers in the quarter. In ongoing partner-sponsored clinical studies with MultiTAA T cells at Baylor College of Medicine, patients are experiencing durable responses, some over 5 years, with virtually no meaningful treatment-related toxicities. And while it's early days, we are encouraged by the promising results delivered by our novel T-cell immunotherapy particularly in such challenging disease areas.

In anticipation and support of future Marker-sponsored clinical trials, we continue to build out our infrastructure and expand our team. We anticipate the next 12 to 18 months to be an exciting and productive time for our company.

As you may recall, based on the breadth of data collected across the Baylor-sponsored studies, we have selected acute myeloid leukemia, or AML, as our lead indication for our first company-sponsored clinical trial. We recently filed a new Investigational New Drug application, or IND, with the U.S. FDA as part of a planned Marker Phase II study in post-allogeneic hematopoietic stem cell transplant patients with AML in both the adjuvant and active disease settings. Upon reviewing our submission, the FDA requested additional information regarding certain quality and technical specifications for 2 reagents supplied by third-party vendors that are used in our manufacturing process. These reagents are ancillary products used in manufacturing and are not present in the final product. However, because the data are needed to clear the IND, the trial has been placed on hold until our complete response to the technical questions is deemed satisfactory to the FDA.

Because the agency's questions were directed to third-party products rather than our own process or product, we worked with the regulatory and quality groups at the respective manufacturers to address the FDA's request. After receiving the required information from them, we submitted our complete response to the agency in late October, and regulators have 30 days to respond. We will communicate an update and our plans to move forward once these questions have been addressed. Given the various resolution scenarios, we are confident that we can initiate the trial in 2020 and hope to provide more precise time lines later this year.

We recognize the need for new, improved therapies in AML. And advancing our novel T-cell candidate, which we believe can have a significant impact on the treatment of this patient population, remains our top priority. In fact, AML is the most common acute leukemia in adults and progresses rapidly without treatment. The prognosis for these patients is poor with a 5-year survival rate of 28% and a high risk of relapse necessitating the need for improved treatments. Current options are mostly limited to chemotherapy, sometimes in combination with a bone marrow transplant. Both treatments carry a risk of bleeding, life-threatening infections and permanent infertility. Bone marrow transplants also carry risk of graft-versus-host disease, also known as GVHD.

We believe that our MultiTAA therapy may have several advantages over standard approaches as well as other T cell therapies in development. In contrast to monospecific T cells, MultiTAA T cells recognize up to 5 antigens and allow for epitope spreading, leading to a more potent, durable antitumor response. And unlike transplants that require hospital stays, MultiTAA is administered in an outpatient setting.

MultiTAA-based cell therapy is our central focus, but we are also advancing several legacy vaccine-based programs. To date, clinical results in our breast cancer trials have showed continuing progress, including, based on a preliminary analysis of 34 patients enrolled in a triple-negative breast cancer trial to date, 31 have showed meaningful immune responses to vaccine treatment. Of 80 patients treated at 11 clinical sites, 14 have shown disease progression as of September 30, 2019, following treatment with TPIV200.

We have, however, made the decision to discontinue the development of our cancer vaccine in patients with platinum-sensitive advanced ovarian cancer based on an unblinded review of interim results from our Phase II study conducted by an independent Data and Safety Monitoring Board, or DSMB. Although the DSMB did not express any safety concerns with respect to TPIV200, we have elected to suspend the trial as it did not meet our threshold for probability of success based upon our prespecified criteria. Pending full review of the data, we anticipate closing the trial in the first quarter of 2020.

Unlike the ovarian cancer trial, there is no formal interim analysis in the breast cancer trial. The last patient will complete the trial in Q2 2021, at which time we will communicate the results and make a decision on next steps for that product.

With that, I will turn the call over to Tony to review financials. After that, we look forward to taking your questions.

--------------------------------------------------------------------------------

Anthony H. Kim, Marker Therapeutics, Inc. - CFO [4]

--------------------------------------------------------------------------------

Thanks, Peter. Net loss for the quarter ended September 30, 2019, was $5.5 million compared to a net loss of $4.4 million for the quarter ended September 30, 2018.

Research and development costs during the 3 months ended September 30, 2019, was $3.1 million compared to $1.9 million during the 3 months ended September 30, 2018. The increase of $1.2 million was primarily attributable to increases in personnel-related expenses relating to the buildup of our internal infrastructure.

General and administrative expenses were $2.5 million during the 3 months ended September 30, 2019, as compared to $2.6 million during the 3 months ended September 30, 2018. The decrease was primarily attributable to $0.6 million of merger-related expenses incurred during the 3 months ended September 30, 2018, offset by increased expenses in head count-related legal and other professional expenses.

I will now turn the presentation back over to Peter for final remarks.

--------------------------------------------------------------------------------

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [5]

--------------------------------------------------------------------------------

Thanks, Tony. I'll open the call for questions. Operator?

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first question comes from Christopher Marai with Nomura Instinet.

--------------------------------------------------------------------------------

Jackson Dean Harvey, Nomura Securities Co. Ltd., Research Division - Research Analyst [2]

--------------------------------------------------------------------------------

This is Jackson Harvey on for Christopher Marai. I'm just curious, after the FDA resolves the clinical hold with the response to their technical concerns, how quickly will you be able to start dosing patients?

--------------------------------------------------------------------------------

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [3]

--------------------------------------------------------------------------------

Thanks for the question. That's a great question. We've not stood still in the meantime. In fact, I think that preparations for initiation of the trial are fully underway. In fact, we're progressing ahead of plan in the site enrollment plan. To date, we have visited over 20 sites who are now waiting for an accepted IND number. Once we have an accepted IND number, we can get the IRB and contracting process started with those sites. And so I do anticipate that we should be able to start the trial promptly after acceptance of the IND.

--------------------------------------------------------------------------------

Operator [4]

--------------------------------------------------------------------------------

Our next question comes from Ted Tenthoff with Piper Jaffray.

--------------------------------------------------------------------------------

Edward Andrew Tenthoff, Piper Jaffray Companies, Research Division - MD & Senior Research Analyst [5]

--------------------------------------------------------------------------------

Just following up on that, what are some of the outstanding issues with respect to the IND hold? And just to be a little bit clearer on timing, what are the next steps exactly? I want to make sure I understand that.

--------------------------------------------------------------------------------

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [6]

--------------------------------------------------------------------------------

Yes, absolutely, Ted. Why don't I turn the question over to Mythili Koneru, our Head of Medical Operations?

--------------------------------------------------------------------------------

Mythili Koneru, Marker Therapeutics, Inc. - SVP of Clinical Development [7]

--------------------------------------------------------------------------------

Regarding -- thank you, Peter. To address your -- the first part of your question, the FDA requested additional information specifically regarding certain quality and technical specifications for 2 reagents that were supplied by a third-party vendor that we use in our manufacturing process, but it's actually not present in the final product infused to patients. So because the FDA requires these data before planning -- allowing any of these planned studies to move forward under this IND, the IND was placed on clinical hold until our complete response to the technical questions is satisfactory to FDA.

So the idea that as we communicated in the press release, we've been working with the regulatory and quality groups at these respective manufacturers to address the FDA's request. And we've submitted a complete response to these issues that was raised by the FDA on October 28, 2019. So the FDA is going to respond within 30 days after receiving the complete responses and then indicate whether the hold is actually lifted. And if not, specifically the reasons why the clinical trial...

--------------------------------------------------------------------------------

Edward Andrew Tenthoff, Piper Jaffray Companies, Research Division - MD & Senior Research Analyst [8]

--------------------------------------------------------------------------------

That's really, really helpful because I think it puts into perspective just how maybe, hopefully, minor that says for the IND. So all the best in getting that up and going, and we're excited to hear more about the studies.

--------------------------------------------------------------------------------

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [9]

--------------------------------------------------------------------------------

Thanks, Ted. We really do see it as sort of not atypical from what we're seeing across the industry in biologics right now -- in cell therapy. So appreciate it.

--------------------------------------------------------------------------------

Operator [10]

--------------------------------------------------------------------------------

Our next question comes from Matt Biegler with Oppenheimer & Company.

--------------------------------------------------------------------------------

Matthew Cornell Biegler, Oppenheimer & Co. Inc., Research Division - Associate [11]

--------------------------------------------------------------------------------

Peter, what do you think really could be a worst-case scenario here with this IND delay? Do you think the FDA might require you to find a new vendor for those reagents that you mentioned? And if so, I mean how long would you estimate it would take to do equivalence testing?

--------------------------------------------------------------------------------

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [12]

--------------------------------------------------------------------------------

Yes. Matt, that's a good question. Let me once again refer to Mythili here. From what I can say, I think that the FDA acceptance at this point is really the gating item for us to start. Like I said, the site enrollment has gone, if anything, better than expected. And so I do think that we should be able to get pretty fast start as soon as we get acceptance.

My, do you have anything further to add?

--------------------------------------------------------------------------------

Mythili Koneru, Marker Therapeutics, Inc. - SVP of Clinical Development [13]

--------------------------------------------------------------------------------

Yes. I just would like to reiterate that we have been working very closely with these respective manufacturers and have submitted the response to the FDA's question. We do expect to initiate the Phase II clinical trial of our MultiTAA program for the treatment of post-transplant AML in 2020, and we feel confident about that.

--------------------------------------------------------------------------------

Matthew Cornell Biegler, Oppenheimer & Co. Inc., Research Division - Associate [14]

--------------------------------------------------------------------------------

Okay. That's helpful. And so the agency didn't have any concerns with the actual design of the AML trial, and you're still planning on moving forward with that same design, looking at both relapsed/refractory as well as maintenance patients, is that correct?

--------------------------------------------------------------------------------

The rest is here:
Edited Transcript of MRKR.OQ earnings conference call or presentation 12-Nov-19 10:00pm GMT - Yahoo Finance

Crystal market research acknowledges the inclusion of a second report to a Global Biotechnology Market. The report summarizes the players that are perceptible in the Biotechnology market with an exact objective to provide a rationalist and purpose of their unpretentious forces of this current Biotechnology market, as the provincial and product segments are likewise expected at length, bearing in mind the Biotechnology objective to grant a granular example of this economys collapse.

The Biotechnology report expands coverage of business and market trends that are chief. The Biotechnology industry research incorporates require, predictions and classical market data, application information and cost trends, and business stocks. The Biotechnology analysis divides the sector dimensions, by price and volume, dependent on geography and application type.

Get the FREE PDF of this Research Report Now! @https://www.crystalmarketresearch.com/report-sample/HC012294

Continued

Inquiry More about this Research Report Now!: https://www.crystalmarketresearch.com/send-an-enquiry/HC012294

Check Exclusive Discount on this report @https://www.crystalmarketresearch.com/check-discount/HC012294

Contacts Us:

Sherry | APAC Marketing Division: Level 23-1, Premier Suite

Mont Kiara, 50480 Kuala Lumpur

Malaysia

E-mail: sales@crystalmarketresearch.com

Read more from the original source:
New innovative report on Biotechnology Market to Boom In Near Future by Industry Key Players: Merck & Co,Abbott Laboratories,Novo Nordisk - Day...

Shutterstock

China is rapidly gaining on the United States when it comes to creating technology that mitigates disease threats and developing pharmaceuticals faster, and its a phenomenon driven by a philosophy that the state, military, and the private sector are one in the same.

That was the testimony of Tara J. OToole, senior fellow and executive vice president at In-Q-Tel, before the U.S. Senate Armed Services Subcommittee on Emerging Threats and Capabilities. The hearing, Biological Threats to U.S. National Security, examined everything from Chinas push to develop biotechnology infrastructure to luring research scientists away from the United States to work in China.

China has said repeatedly and forcefully, and theyre backing up their words with actions, that they intend to own the biorevolution, OToole said. And they are building the infrastructure, the talent pipeline, the regulatory system, and the financial system they need to do that.

China is partly accomplishing this by combining its internet giants, such as Alibaba, with its biotech companies. The combined strength of these companies research focuses on the industrialization of artificial intelligence in which China is institutionalizing it whereas the United States is only experimenting with it, OToole added.

Chinas goal is to make biotechnology 5 percent of the countrys GDP by 2020. China has changed regulations for its own version of the Food and Drug Administration to be more like that of the United States in order to more easily market to the world. The country has created a talent pipeline that incentivizes its own students to go into the life sciences and bioengineering. China also has at least 20 programs intended to bring scientific talent from the rest of the world.

There are good reasons China is going after the biorevolution: it has the highest incidences of cancer on earth and the population is aging. It also must find an affordable way to deliver health care to a rising middle class.

And China is delivering health care to the world. The country is the largest producer of active pharmaceutical ingredients. However, reliance on foreign pharmaceuticals has national security implications. As many as 80 to 100 percent of critical drugs are manufactured outside the United States. U.S Sen. Gary Peters (D-MI) told the committee that following the 2001 anthrax attacks, the U.S. was dependent on a single foreign source for a broad-spectrum antibiotic to treat anthrax.

To what extent is the U.S. reliant on foreign sources for key drug products and medical supplies such as syringes and needles and other critical medical supplies that we would need to respond to a biological attack today? Peters asked the panel of experts.

The United States is critically dependent on China for several drugs and has been shipping manufacturing capacity to Asia for more than a decade.

There isnt a CEO of a major pharma company that hasnt been recruited by China to build facilities there, OToole said.

To address the drug supply chain, the United States has begun exploring the possibility of using synthetic biology to make active pharmaceutical ingredients, especially in response to epidemics.

If there were a natural pandemic in which the entire world needed drugs, Im sure China, as we would, take care of its own people first. Yet, we dont have the surge capacity to produce enough very common, well-used medicine in time to deal with an epidemic, OToole said.

Thomas Inglesby, director of the Center for Health Security at the Johns Hopkins Bloomberg School of Public Health, told the committee that the U.S. treats medicines too much like commodities that can be sourced for the lowest price somewhere in the world.

In a crisis, everyone in every part of the world would be looking for medicine at the same time, Inglesby said. There should be at least a strategic examination of the kinds of things we must have, and we should consider how to bring some of those medicines back to the U.S. Obviously that cant be done with all medicines. Were an interconnected world. But for national health crises, we should be thinking about making them here.

Part of the problem is that the United States has not done a good job at translating biology to products, OToole said, or building infrastructure for securing and promoting the bioeconomy. Our translational infrastructure for biology is mostly coming from small start-up companies in the private sector, which are the innovation engines for biology, but do not provide the robust infrastructure to manage epidemics, whether deliberate or natural.

The experts made the following recommendations:

* Take on synthetic biology as a national security priority;* Use the National Defense Education Act to improve access to stem education and establish greater scientific careers within the U.S. government;* The contingency fund levels for the Centers for Disease Control and Prevention and USAID should be increased and sustained;* Support and strengthen the militarys infectious disease research laboratories;* Provide strong, coherent leadership at the National Security Council essential for guaranteeing effective oversight, long before a crisis emerges;* The U.S. Department of Agriculture should prioritize stronger crop surveillance, animal wildlife surveillance, more support for animal vaccine development, and more funding for agricultural biodefense overall;* Strongly support the biological weapons convention.

During epidemics, the U.S. should be able to immediately create diagnostics that could be used similarly to a pregnancy test so that people can determine for themselves who is sick and who isnt. Officials should be able to rapidly develop a new vaccine in response to an epidemic, OToole added.

These same tools also apply to diseases that affect agriculture and the U.S. animal supply. More than half of all infections that people contract are spread by animals.

Ill start by acknowledging that mother nature is a really good terrorist, Julie L. Gerberding, co-chair of the Commission on Strengthening Americas Health Security at the Center for Strategic and International Studies, told the committee. China today is experiencing a dreadful outbreak of swine fever that has probably cost the death or culling of at least 50 percent of their entire population of pork which is a major source of protein for people in China. So, this is a major socioeconomic threat to the state of China today and thats mother nature.

Swine fever, however, is not spread to humans, though it has a devastating economic impact. And U.S. farmers are concerned about trade and travel bringing such infectious diseases to this country.

I would say that the first alarming statistic is that we spend probably about 100 times less on agricultural threats than we do on human threats, Inglesby said. I think there are many reasons for this. But one includes a kind of reluctance within the U.S. government to talk about this threat until quite recently.

Continue reading here:
Chinese biotechnology dominates US Senate hearing on biological threats - Homeland Preparedness News

On the second floor of the Pennovation Center, Strella Biotechnology is hard at work turning their student-led startup into a full-fledged company thats ready to make a major impact in the agricultural sector.

May graduates Katherine Sizov and Malika Shukurova, respectively the CEO and head of R&D at Strella, share a 2019 Presidents Innovation Prize, which includes $100,000 of financial support, a $50,000 living stipend for both awardees, and a year of dedicated co-working and lab space at the Pennovation Center. The alumnae and their company are now poised to take on the challenge of $1 trillion worth of food waste.

Strellas biosensors are designed to give packers real-time data on how ripe their fruits are while being stored between harvesting and selling. Using bio-inspired sensors that measure the ethylene gas produced by fruits as they ripen, Strella successfully hacked the fruit to create their patent-pending biosensors. Now, only six months after graduation, Strella has six paying customers and is aiming for $100,000 in sales by the end of the season.

Beyond the work needed to deploy their first paid product, Strella also has a clear view of what needs to be done for future progress of the company. This means running experiments in the lab to refine their current sensors while conducting other experiments that will help the company be able to monitor other types of fresh foods. Its a job that Shukurova says involves a lot of multitasking and requires an all-hands approach to problem solving.

We set up experiments that run for several days, and during that period we work on different tasks. I prepare for the next set of experiments, Jacob [Jordan] and Katherine travel to our customers to deploy sensors, and Zuyang [Liu]]works on IoT [Internet of Things]. At the end of the day we all come together to discuss results and future plans, says Shukurova about their companys work flow.

The company is also finding ways to expand their technology onto individual pallets in retail settings, which represents a huge untapped market for managing food waste. That opportunity, from a numbers perspective, is far greater than the current packing market were working in, so were hoping to make an impact as we move into that space as well, says Sizov.

During the next six months, the team will be busy analyzing the data collected by their deployed sensors and gearing up for a new round of fundraising. Looking further ahead, Strella aims to increase sales in their initial market, conduct research and development on individual pallet-level sensors, and begin active partnerships with larger retailers to help optimize their supply chains.

Sizov admits that Strella has an ambitious timeline but that the team is looking forward to the challenge. Working alongside Jordan, Liu, and Shukurova, Sizov says that Strella already has its own culture of sorts. None of us have ever had a business before, and learning how to create culture within a group, how to work together as a team, and how to not get tired of each other because we spend so much time together, has been an interesting challenge, says Sizov.

Their lab and coworking space at Pennovation has allowed Strella to stay connected with Penns innovator community while also providing lab facilities and resources needed to continue their work on their sensors. Strella has two lab benches and a fume hood, access to shared lab equipment, and plenty of space to house their prototypes, all provided for free as part of their Innovation Prize.

Theyve also been able to stay well-connected to the Penn community as a whole, traveling regularly to campus to meet with faculty, including weekly meetings with their mentorJeffrey Babin. We are not out of [the] Penn mindset, says Shukurova. We dont have to worry about exams, but were still on campus and were still involved with the faculty.

Babin says that Strella is one of the most exciting companies that Ive seen come out of Penn and that the company is in a strong position to make some significant impact on the food supply chain. One of the things thats been strong since the beginning was having an expanded vision: Not just on product development, but getting a customer, he says. They have a really strong sense of whats required to acquire a customer, what the next steps are, and growing both within the initial customer base while expanding to other elements.

When asked what advice they would give to would-be entrepreneurs, Shukurovas advice is to take it as a journey. She encourages students who have an idea to share their thoughts with others to get feedback before beginning any startup endeavor. Talk to more peopledont limit yourself to 10 people, or 20 people, talk to hundreds of people, she says.

Sizov says that the experience of running a startup has been a great learning experience, one that is far less risky than might seem at first, especially thanks to the Innovation Prize. If youre just following your passion, thats not a risk. Youre not putting aside your career, she says. Everything we learn at Strella is directly teaching us how to be better and smarter individuals.

Jeffrey Babin is a practice professor and associate director of the Engineering Entrepreneurship Program in the School of Engineering and Applied Science.

Homepage photo: Presidents Innovation Prize winners Katherine Sizov and Malika Shukurova (front) doing R & D to help design new versions of their fruit-hackingbiosensors at the Pennovation center.

Original post:
Strella Biotechnology tackles food waste by 'hacking the fruit' - Penn: Office of University Communications

Aravive Inc (ARAV) is near the top in its industry group according to InvestorsObserver. ARAV gets an overall rating of 81. That means it scores higher than 81 percent of stocks. Aravive Inc gets a 98 rank in the Biotechnology industry. Biotechnology is number 87 out of 148 industries.

Click Here to get the full Stock Score Report on Aravive Inc (ARAV) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 81 means the stock is more attractive than 81 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aravive Inc (ARAV) stock has fallen -15.53% while the S&P 500 has gained 0.17% as of 10:44 AM on Wednesday, Nov 27. ARAV is lower by -$1.46 from the previous closing price of $9.40 on volume of 1,348,672 shares. Over the past year the S&P 500 has risen 17.28% while ARAV has gained 43.06%. ARAV lost -$6.00 per share the over the last 12 months.

To screen for more stocks like ARAV click here.

View post:
Where Does ARAV Stock Rank in the Biotechnology Industry? - InvestorsObserver

I had one of those way-cool moments and what I now call the most memorable experience of my life this past week in Mombasa, Kenya.

It all started in late October, when I received an invitation from the African Agricultural Technology Foundation (AATF) to attend the Open Forum on Agricultural Biotechnology in Africa (OFAB) 2019 Media Awards on Nov. 21.

The AATF is a nonprofit organization focused on providing smallholder farmers in sub-Saharan Africa with practical technology solutions capable of addressing their farm productivity constraints and improving their livelihoods. One of its initiatives is OFAB, which works to enhance knowledge-sharing and awareness on agricultural biotechnology across seven African countries: Kenya, Tanzania, Ghana, Ethiopia, Uganda, Nigeria and Burkina Faso.

Exactly 18 days after receiving AATFs invitation, OFAB-Nigeria named me best agricultural biotechnology reporter in the print and online category and overall journalist of the year for my entry GMO debate affects public sentiment in Nigeria. I understood then that AATFs email was but a confirmation that I would be representing Nigeria at the continental level of the media awards in Mombasa.

As is typical of Mombasas fluctuating tropical climate, it was a relatively cool evening when the crme de la crmeof Africas science journalists joined scientists and policymakers from the seven OFAB countries for the media awards ceremony at the Sarova Whitesands Hotel. Dressed in a light-blue striped, knee-level kaftan, a black cap and a green-white-green traditional scarf, I joined the throng of people dressed primarily in their own colorful national and traditional garb.

Eugenia Abu, a veteran multimedia journalist who spoke on behalf of the panel of judges, said the awards were intended to acknowledge excellence in science journalism. We congratulate all the winners and urge for more synergy between science and journalism to enable AATF and OFAB to promote better lives for small-holder farmers on the continent through technology, Abu said.

As the crowd cheered, I heard my name announced as the winner in the print and online category. Visibly excited, but also bewildered, I began making my way to the stage. Many thoughts raced through my head at that auspicious moment, such as why are farmers in Africa slow in adopting agricultural innovations? I recalled that in developing my award-winning piece, I had interviewed many people on the streets who did not know what genetically modified organisms (GMOs) are or understand the term biotechnology.

Moreover, I thought again, studies have shown that our current trajectory for crop yields is insufficient to nourish the worlds population by 2050. Hence, with the worlds growing population and climate change, theres a need for greater and more consistent food production around the globe. This is particularly true in Africa, which is projected to hit 2.2. billion people by 2050.

Africa cannot achieve food sufficiency or realize its dream of becoming the food basket of the world without farmers having access to improved seeds, agricultural tools and technology on their farms. Thus journalists have a critical role to play in informing and educating African farmers and consumers about advances in modern agriculture and ensuring that farmers have access to options, including biotechnology. My aim is to connect these scientific innovations and technology to farmers in Africa through better communication.

On Nov. 23, as my Ethiopian Airlines return flight touched down in Abuja, I was filled with a sense of satisfaction for all that had transpired in Mombasa as well as nostalgia for the incredibly talented African journalists with whom I had shared the homey hospitality of the Sarova Whitesands Hotel for the past three days.

As a science journalist, I also felt a strong reconfirmation of my belief that Africas agriculture needs science and technology more than any other continent in the world. Consequently, African journalists must understand and believe in the potential of science and technology so as to report, write and communicate science accurately and spur economic development on the continent.

Asante!

Abdullahi Tsanni is a Nigerian science writer and Alliance for Science contributor.

Read the rest here:
Using media to connect African farmers with scientific innovation and technology - Alliance for Science

Robert W. Baird began coverage on shares of Vir Biotechnology (NYSE:VIR) in a report released on Wednesday, November 13th, The Fly reports. The firm issued a neutral rating on the stock.

Other analysts have also issued reports about the company. Cowen assumed coverage on Vir Biotechnology in a report on Tuesday, November 5th. They set an outperform rating on the stock. Goldman Sachs Group began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued a buy rating and a $37.00 price objective on the stock. Barclays began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Vir Biotechnology currently has an average rating of Buy and an average target price of $29.00.

VIR stock traded up $0.07 during trading hours on Wednesday, hitting $11.90. 101,085 shares of the stock were exchanged, compared to its average volume of 164,664. Vir Biotechnology has a 12 month low of $11.65 and a 12 month high of $16.50.

Vir Biotechnology (NYSE:VIR) last posted its quarterly earnings data on Tuesday, November 19th. The company reported ($4.60) earnings per share for the quarter, missing the consensus estimate of ($3.71) by ($0.89). The business had revenue of $1.40 million during the quarter.

In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf bought 950,000 shares of the companys stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of $14.22 per share, for a total transaction of $13,509,000.00. Also, insider Abu Dhabi Investment Authority bought 1,000,000 shares of the companys stock in a transaction on Wednesday, October 16th. The shares were acquired at an average price of $14.41 per share, with a total value of $14,410,000.00.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Further Reading: What are the qualifications of a portfolio manager?

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
Vir Biotechnology (NYSE:VIR) Coverage Initiated by Analysts at Robert W. Baird - TechNewsObserver

Global Biotechnology Marketis expected to grow at a CAGR of 14% to reach US$ 1,254.1 million in 2024. The growth is coupled with rising demand of modern and innovative technologies such as DNA sequencing, recombinant technology, fermentation, tissue engineering. Further, rising demand for food to meet the need of ever increasing population and scarce availability of non-renewable natural resources also expected to drive the biotechnology market. Application of Genetic engineering and Genetic Modification (GM) processes to agricultural food products also expected to drive the business growth. Furthermore, decreasing prices of DNA sequencing technologies will encourage R&D activities to better understand genetic variations and develop therapeutic solutions.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/10844

Moreover, development of novel techniques and their implementation by the organisation by collaborating with the other participants will drive the Global Biotechnology Market. Further, increasing demand for therapeutic and diagnostic solutions on principles of red biotechnology, DNA sequencing, and recombinant technology is expected to drive the Global Biotechnology Market through 2024. Increasing prevalence of diseases such as hepatitis B, cancer, and other orphan disorders is also expected to fuel demand in the forecast period.

In 2017, North America dominated the overall market. The market growth is driven by the increasing R&D investments relating to new drug discovery and development. U.S. held highest market in North America due to increasing level of per capita spending on healthcare than other countries and has a high growth rate amongst other countries. According to the estimates published by OECD Health Statistics in 2014, it has been estimated that in 2012, U.S. spent nearly 16.9% of its GDP towards healthcare expenditure, which is the highest. The fact supports the estimated share of Global Biotechnology Market.

Asia Pacific is expected to have higher growth rate in the forecast period owing to the presence of patient awareness, rapidly improving healthcare infrastructure, and rising healthcare expenditure levels in the emerging markets. Global Biotechnology Market include the developing economies of China and India.

In 2017, nanobiotechnology held the highest market share. The Global Biotechnology Market growth is driven by fermentation and cell-based assay segments owing to rising R&D initiatives by various biotechnological and pharmaceutical companies.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/10844

Global Biotechnology Market

Market Segmentation By Technologyo DNA Sequencingo Nanobiotechnologyo Tissue engineering and Regenerationo Fermentationo Cell Based Assayo PCR Technologyo Chromatography Marketo Others

By Applicationso Healtho Food & Agricultureo Natural Resources & Environmento Industrial Processingo Bioinformaticso Others

The above data will be provided for following regions/countries from 2013-2024 (USD Million)

North Americao U.S.o Canada

Europeo Germanyo UKo Franceo Spaino Italy

Asia Pacifico Chinao Indiao Japano Australia

Latin Americao Argentinao Brazilo Mexico

Middle East and Africao South Africao Saudi Arabia

MAJOR TOC OF THE REPORT

Chapter One: Biotechnology Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Biotechnology Market Competition, by Players

Chapter Four: Global Biotechnology Market Size by Regions

Chapter Five: North America Biotechnology Revenue by Countries

Chapter Six: Europe Biotechnology Revenue by Countries

Chapter Seven: Asia-Pacific Biotechnology Revenue by Countries

Chapter Eight: South America Biotechnology Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Biotechnology by Countries

Chapter Ten: Global Biotechnology Market Segment by Type

Chapter Eleven: Global Biotechnology Market Segment by Application

Chapter Twelve: Global Biotechnology Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Biotechnology Market Report at:https://www.maximizemarketresearch.com/market-report/global-biotechnology-market/10844/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read more here:
Global Biotechnology Market : North America Is Expected To Account For Higher Market Share Of More Than 45% Driven By Increasing Investment In Us On...

PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that Lauren V. Wood, M.D., Chief Medical Officer of PDS Biotechnology, has been selected to deliver an oral presentation on the Companys novel T-cell activating immunotherapy platform, Versamune, at the World Vaccine & Immunotherapy Congress West Coast 2019, taking place on December 2-5, 2019 in San Francisco, CA.

Details for the presentation are below:

Presentation Title: Versamune: A Novel T-cell Activating Immunotherapy PlatformTopic: Engaging T-Cells, Cancer Antibodies, and CombinationsPresenter: Dr. Lauren V. Wood, Chief Medical Officer, PDS BiotechnologyDate: Wednesday, December 4, 2019Time: 3:00pm PST

The Versamune platform is PDS Biotechs proprietary, synthetic lipid-based T-cell activating platform, which works by facilitating several critical immunological pathways. Versamunes mechanism of action involves the effective cross-presentation of tumor antigens via the MHC Class I and Class II pathways to prime tumor-specific CD8+ and CD4+ T-cells as well the potent up-regulation of Type 1 interferon genes within the lymph nodes, promoting effective T-cell migration, activation and proliferation. These mechanisms promote strong in-vivo induction of polyfunctional tumor-targeting CD8+ killer T-cells. Versamunes activation specifically of type 1 interferons coupled with the lack of significant systemic cytokine release results in a highly favorable safety profile that has potential uses in combination with checkpoint inhibitors and other therapeutic agents. In a phase 1 human clinical trial PDS Biotechnologys lead Versamune-based immunotherapy exhibited potent antigen-specific CD8+ T-cell induction with an average of over 20-fold increase in the blood circulation within 14 days of treatment. The strong T-cell induction also resulted in complete regression of lesions in the majority of treated cervical intraepithelial neoplasia (CIN) patients. The ability to induce high levels of CD8+ killer T-cells in vivo has resulted in potent synergy with checkpoint inhibitors in preclinical studies. Upcoming phase 2 clinical trials to confirm the unique synergy will also be presented.

About PDS Biotechnology

PDS Biotechnology is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechnologys pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotechnologys lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck and the National Cancer Institute (NCI), PDS Biotechnology is advancing PD0101 to Phase 2 studies in head and neck cancer and in HPV-related advanced cancer.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability of the Company to integrate Edge and PDS Biotechnology following the merger; the Companys ability to protect its intellectual property rights; competitive responses to the completion of the merger; potential adverse reactions or changes to business relationships resulting from the completion of the merger;the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Story continues

Read this article:
PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 - Yahoo Finance

REPORTING FOR 2019-11-28 | WCX19.ORG: We have done an in-depth analysis of how PDSB has been trading over the last 2 weeks and the past day especially. On its latest session, PDS Biotechnology Corporation (NASDAQ:PDSB) opened at 2.22, reaching a high of 2.38 and a low of 2.1007 before closing at a price of 2.27. There was a total volume of 37786.

VOLUME INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We saw an accumulation-distribution index of 7.27226, an on-balance volume of -2.08, chaikin money flow of 2.49125 and a force index of 1e-05. There was an ease of movement rating of 0.0024, a volume-price trend of -1.16026 and a negative volume index of 1000.0.

VOLATILITY INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We noted an average true range of 0.2508, bolinger bands of 2.11962, an upper bollinger band of 2.06108, lower bollinger band of 2.1007, a bollinger high band indicator of 1.0, bollinger low band indicator of 1.0, a central keltner channel of 2.23357, high band keltner channel of 2.07357, low band keltner channel of 2.39357, a high band keltner channel indicator of 1.0 and a low band keltner channel indicator of 1.0. There was a donchian channel high band of 2.1007, a donchian channel low band of 2.1007, a donchian channel high band indicator of 1.0, and a donchian channel low band indicator of 1.0.

TREND INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We calculated a Moving Average Convergence Divergence (MACD) of -0.00046, a MACD signal of -0.00026, a MACD difference of -0.00021, a fast Exponential Moving Average (EMA) indicator of 2.1007, a slow Exponential Moving Average (EMA) indicator of 2.1007, an Average Directional Movement Index (ADX) of unknown, an ADX positive of 20.0, an ADX negative of 20.0, a positive Vortex Indicator (VI) of 1.0, a negative VI of 1.0, a trend vortex difference of 0.09678, a trix of -42.69843, a Mass Index (MI) of 1.0, a Commodity Channel Index (CCI) of -66.66667, a Detrended Price Oscillator (DPO) of 2.36666, a KST Oscillator (KST) of -529.76734 and a KST Oscillator (KST Signal) of -529.76734 (leaving a KST difference of -1.1584). We also found an Ichimoku rating of 2.3, an Ichimoku B rating of 2.3, a Ichimoku visual trend A of 4.40959, an Ichimoku visual trend B of 3.78933, an Aroon Indicator (AI) up of 4.0 and an AI indicator down of 4.0. That left a difference of -4.0.

MOMENTUM INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We found a Relative Strength Index (RSI) of 50.0, a Money Flow Index (MFI) of 34.08787, a True Strength Index (TSI) of -100.0, an ultimate oscillator of -13.38052, a stochastic oscillator of 174.5625, a stochastic oscillator signal of 174.5625, a Williams %R rating of 74.5625 and an awesome oscillator of -0.00285.

RETURNS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): There was a daily return of -52.97673, a daily log return of -0.99027 and a cumulative return of -0.98539.

What the heck does all of this mean? If you are new to technical analysis, the above may be gibberish to you, and thats OK (though we do advise learning these things). The bottom line is that AS OF 2019-11-28 (if you are reading this later, the analysis will be out of date), here is what our deep analysis of technical indicators are telling us for PDS Biotechnology Corporation (NASDAQ:PDSB)

DISCLAIMER: We are not registered investment advisers and the above analysis should be taken at face value only. We strongly advise against buying or selling PDS Biotechnology Corporation (NASDAQ:PDSB) based solely on our analysis above, and are not responsible for any losses that you may incur if you choose make any investment decisions based on the above.

The rest is here:
PDS Biotechnology Corporation (NASDAQ:PDSB): The Good, The Bad, The Ugly (2019-11-28) - WCX19